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BACKGROUND: Biological variation (BV) data can be used to set analytical performance 
specifications (APS) for lipid assays. Poor performance will impact upon the efficacy of 
international guidelines for cardiovascular risk assessment (CVR) and relevant clinical 
decision limits.  This systematic review applies the Biological Variation Data Critical 
Appraisal Checklist (BIVAC) to published studies of BV of CVR biomarkers enabling 
metanalysis of the data. 
METHODS: Studies of BV of total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglycerides and apolipoproteins A1 and B, retrieved using a systematic literature 
search, were evaluated and graded using the BIVAC.  Meta-analysis of CVI and CVG 
estimates were performed utilizing weightings based upon BIVAC grades and the width 
of the data confidence intervals. 
RESULTS: Applying the BIVAC, ten publications were graded as D, 43 as C, 5 as B and 1 
as A (fully compliant). A total of 196 CVI and 87 CVG estimates were available for the 
different lipid measurands. The meta-analysis-derived BV data estimates were 
generally concordant with those in the online 2014 BV database.  
CONCLUSIONS: Application of BIVAC identifies BV data suitable for many important 
applications including setting APS. Additionally, this review identifies a need for new 
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Cardiovascular diseases (CVD) are a major cause of death and morbidity in developed 
countries [1].  The economic impacts of CVD are significant.  Therefore, there has been 
an international focus on CVD prevention, risk assessment, diagnosis and management 
[2, 3]. The adoption of international guidelines in these contexts has resulted in 
increasing volumes of requests for lipid measurements.  Lipid tests are now amongst 
the most requested tests in laboratory medicine. 
 
Accuracy and precision of lipid measurands, across and between healthcare systems, 
are required for delivery of equitable patient outcomes. Sub optimal analytical 
performance will impact on the   efficacy of international guidelines where fixed 
clinical decision limits are based on a defined measurand value. Analytical 
performance specifications (APS) are required for such measurands.  The European 
Federation of Laboratory Medicine (EFLM) 1st Strategic Conference Consensus 
Statement identified three models for assignation of APS: clinical outcomes, biological 
variation (BV) and state of the art [4]. For lipid measurands in the context of CVD, 
clinical outcome has been identified as the model of choice [5]. In the absence of 
relevant clinical outcome studies, laboratory professionals pragmatically apply the BV 
model. It follows, however, that application of incorrect estimates of biological 
variation to set (APS) will impact upon patient care.  In addition to setting of APS, BV 
data have a number of other relevant and important applications; those include the 
derivation of method validation criteria for IVD providers, the monitoring of laboratory 
analytical performance and establishing reference change values to assess the 
significance of changes in serial results [6-8]. All these applications require access to 
relevant and well characterized BV data. 
 
For many years, access to BV data has been enabled through the work of the Spanish 
Society of Laboratory Medicine (SEQCML). Their collated BV data set has been made 
widely available via an online database which was last updated in 2014 [9].  Criteria 
used to select  data for inclusion in the database have been published [10]. Recently, 
however, concerns have been raised about  the quality and current  applicability of the 
BV estimates included; this has led to  calls for new global BV estimates to be delivered 
using data from studies rigorously appraised against a new set of criteria [11,12]. In 
response, the Working Group on Biological Variation [13] and the EFLM Task Group for 
the Biological Variation Database have developed the recently published Biological 
Variation Data Critical Appraisal Checklist, (BIVAC) [14]. BIVAC is a tool that enables 
appraisal of the methodological quality of BV publications and of the reported BV data 
estimates. In addition, a meta-analysis method has been developed to enable delivery 
of robust global estimates of BV data, with confidence limits, from BIVAC compliant 
studies  [14]. This approach makes available BV data estimates derived from quality 
assessed historical and contemporary studies. 
 
The aims of the systematic review presented here are to use the BIVAC to critically 
appraise published studies of BV of biomarkers used for cardiovascular risk 
assessment. The review enables: (i) collation of data from BIVAC compliant studies for 

















between-subject (CVG) BV and (ii) a review of the effect of study design, differences in 




Material and methods 
 
All published studies of BV of total cholesterol (TC), HDL-cholesterol (HDLC), LDL-
cholesterol (LDLC), triglycerides (TG) and apolipoproteins A1 (Apo A1) and B (Apo B) 
originally included in the online 2014 BV database [9] were retrieved for appraisal. 
Additional studies were identified employing a systematic literature search as 
previously described [14] using the cut-date of September 2018. Within this systematic 
review, all publications referred to from online 2014 BV database are denoted with the 
article number they had been allocated within that source; additionally a  suffix letter 
has been  assigned (a, b, c, etc.) to identify  estimates from subgroup partitions (e.g. 
subjects stratified by age, gender, etc.) identified with the denoted publication.  
 
The retrieved publications were evaluated by application of the BIVAC to verify 
compliance  as evidenced by reporting of  essential methodological elements for a 
study of BV [14]. The methodology of the reviewing process has been described 
previously [14]. Briefly, two independent assessors reviewed each publication. If there 
were discrepancies in the BIVAC scores, a third assessor did a full review of the paper 
and a decision was made. The BIVAC review process assesses and scores 14 quality 
items (QI); study population and design (QI2, QI3, QI5 and QI7), analytical 
methodology (QI1, QI4 and QI6), statistical analysis and reporting of data (QI8, QI9, 
QI10, QI11, QI12, QI13 and QI14) [14]. QI were scored as A, B, C or D, indicating 
decreasing compliance with the BIVAC. The lowest quality score achievedfor any of the 
QIs defines the overall BIVAC grade (A, B, C or D). Studies receiving even a single BIVAC 
QI scored as a  D were considered lacking essential elements and excluded from the 
remainder of the study [14]. 95% confidence intervals (CI) for BV estimates were 
calculated as described by Røraas [15, 16] if the required data  were  provided,(i.e. (i) 
mean number of subjects, (ii) mean number of samples and (iii) estimates of analytical 
variation (CVA)). 
 
Estimates of BV, with 95% CI, from all studies and subgroups were plotted to facilitate 
visual inspection of the data and identification of aberrant data that may  influencing 
the global BV estimates.  We evaluated the influence of health status, age, study 
design (study duration, sampling interval, number of samples, etc.) and methodology 




Meta-analysis of CVI and CVG estimates were performed applying the weighted mean 
as previously described [14], by using the combined result of the inverse width of each 
estimate’s confidence interval (CI) and the BIVAC quality grade (A papers weighted by 

















recorded  separate BV estimates for different subgroups, those estimates were 
combined to provide a common estimate by applying the weighted mean on the point 
estimates and corresponding CIs; this approach minimized the effect of widely 
differing results (e.g. from males and females)  from the same study impacting 
adversely upon the common estimates. Percentile bootstrap with the weighted 
median performed on each of the resampled data sets were used for calculating the CI 
[17]. Only studies performed in healthy adults (age 18-75 years) were included in the 
meta-analysis. Studies receiving BIVAC grade D, studies with within-day samplings, 
studies with less than three samples per subject, and studies lacking the necessary 





In total 59 publications were collated reporting BV data estimates for any of the 7 
measurands of interest. Data were available for both measured and calculated LDL-
cholesterol (Table 1, Supplemental Table 1). Applying the BIVAC, ten of these 
publications were graded as D, 43 as C, 5 as B and 1 as A.  
 
A total of 196 CVI and 87 CVG estimates were available for the various lipid measurands 
were available for objective assessment and analysis. 
 
The BIVAC grade B was given to studies in most cases for non-compliance with 
statistically related quality indicators (QI 8: incomplete outliers testing, QI 9: normally 
distributed data and QI 11: statistical method). Papers graded most commonly graded 
C because of failure to report adequate information to the statistical approach used to 
deliver the BV estimates.  Absence of data implied that some of the key statistical QIs 
were not addressed (e.g. use of appropriate statistics (QI 11), assessment of the data 
set for outliers, (QI 8) and examination for variance homogeneity (QI 10). A BIVAC 
grade D was most frequently the result of an insufficient description of the study 
population (QI 2) or use of obsolete analytical methods (QI 4) [14].  
 
The initial review process identified discrepancies in the scoring of studies by the 
paired reviewers. This amounted to 40% (8 discrepancies in 20 evaluated papers), and 
occurred mostly because of lack of details on statistical procedure in historical papers. 
This required and promoted discussions between assessors to enable a consensus to 
be about the scoring criteria. Following that process, a second stage review of the 
larger number of paper, delivered an agreed BIVAC compliance grade in 95% of cases. 
Of the remaining 5% of the papers (2 discrepancies in 37 evaluated papers), 
discrepancies arose because of issues relating to QIs 8, 9, 10 and 11. Difficulties 
centered around the lack of explanation, details or clarity when describing outliers’ 
detection and statistical methods in these publications were resolved by including a 



















Of the 59 reviewed studies, 57 reported results for TC (Table 1), ten of those were 
graded D, being non-compliant with QI 2 or QI 4 . Only one study achieved an A grade, 
the European Biological Variation Study (EuBIVAS) [18]. 36 papers, reported CVI 
estimates for 55 subgroups and CVG for 25 subgroups, fulfilled the criteria for inclusion 
in the meta-analysis. When estimates from subgroups from the same study were 
combined (e.g. men and women), this delivered a total of 34 CVI estimates and 17 CVG 
estimates for inclusion in the meta-analysis (Table 2). The meta-analysis delivered 
about similar point estimates as those available in the online 2014 BV database (Table 
2), but with an added attribute in the form of CI. 
 
On visual inspection of the TC data, no relationship was observed between BV 
estimates and the age of the subjects studied (Figure 1). Based on visual inspection 
and analysis of the data, CVI results of the study identified as number 290, subgroup 
“a” for TC and HDLC were classified as outliers and excluded from the meta-analysis. 
Only a few of the included papers provided CVG estimates, here estimates from non-




Forty-one papers included results for TG. Twenty-seven of them were included in 
meta-analysis, with CVI reported for 42 subgroups and CVG reported for 17 subgroups. 
A total of 27 CVI and 12 CVG estimates were identified for inclusion in the meta-analysis 
(Table 2). A wide dispersion in CVI estimates was observed for TG (Figure 3) with very 
variable confidence limits. Also, the CVA estimate reported in paper number 53 which 
was higher than those of other studies. This  was a C graded paper that included 
weekly sampling from 5 women following a controlled diet. Based on visual inspection 
of results, health status does not appear as a factor who influencing BV (Figure 3, 
Supplemental Figure 1). 
 
HDL-cholesterol 
Thirty-two papers reported BV data for HDLC and 21 of them met the criteria for 
inclusion in the meta-analysis, with estimates of CVI and CVG for 31 and 10 subgroups 
respectively, delivering a set of 20 data points for CVI and 6 for CVG (Table 2). 
 
Figure 4 shows the CVI estimates from the collated HDLC studies; the CVI estimate 
from paper number 290, a study performed in Chinese healthy subjects, is an evident 
outlier for CVI . The CVI estimate was higher than that of other studies (Figure 4), 
however the CVG estimate did not appear different (Supplemental Figure 2). Visual 
inspection of data identified that paper 255 delivers CVG estimates for non-healthy and 
healthy sub-groups that are both higher than other estimates and exhibit a wide CI. 
This paper is a B graded paper; it reported on a study performed in 11 healthy Spanish 
subjects (8 females and 3 males, age range: 20-50). The measurement procedure, 
analytical variation and other assessed variables did not differ from the rest of studies.  
 

















Fourteen papers fulfilled the inclusion criteria for calculated LDLC, and 6 papers met 
these criteria for measured LDLC (Table 2). On visual inspection, there seems not to be 
any difference between measured and calculated LDLC CVI estimates based on studies 
in healthy adult subjects (Figure 5, Supplemental Figure 3). Only a limited number of 






CVD presents many challenging healthcare issues to developed countries. Significant 
workloads accrue to clinical laboratories as a consequence of national and 
international guidelines applying to diagnosis and management of CVD that require 
lipid analysis. Laboratory measurements of lipids and lipoproteins are of utmost 
importance to ensure the correct classification of subjects in terms of cardiovascular 
risk, monitoring response to treatment and follow up [19]. The analytical performance 
of assay systems will impact diagnostic efficiencies, disease monitoring and 
management, delivering a requirement for defined APS.  
  
It has been proposed that APS for the measurement of total cholesterol, HDLC and 
LDLC should be assigned using the clinical outcome model [5]. The rationale for this is 
based on the use of clinical cut-offs recommended by guidelines to classify patients 
into different groups for pharmacological treatments, other interventional strategies 
or combinations of both. Paradoxically, triglyceride measurement is recommended to 
be assigned to the alternative BV model to determine APS even though the result is 
used to calculate LDLC [5].  
 
While the application of the outcome model may be the ideal for many CVD relevant 
lipid and lipoprotein measurands, the required outcome data are scarce. Also APS 
derived using the outcome model may not be appropriate to all clinical applications of 
an assay. This is important as the results of an analytical method deployed in a central 
laboratory   may be applied in many clinical situations and in the context of mixed 
pathologies, thus applying APS criteria based on a single disease specific clinical 
outcome model, may not be generally valid. An alternative approach to setting valid 
APS using BV data may also prove challenging if the quality of the reference data is 
poor [13]. The latter can be addressed by application of BIVAC and use of meta-
analysis which together provide approaches to deliver quality assessed BV data for 
such applications [14].   
 
Our study shows that BV estimates for lipids delivered by meta-analysis of data from 
BIVAC compliant studies are of the same order as those made available in the online 
2014 BV database [2]. All CVI and CVG estimates from that source fall into the CI of the 
newer meta-analysis-derived estimates. This observation contrasts with that made of 
BV of enzymes where the meta-analysis estimates in general were lower [14, 21]. A 
possible explanation of this difference is that analytical methods for enzymes have 

















been used in historical publications to calculate BV data. The number of studies 
providing estimates using older methods included in the online 2014 BV database are 
proportionally higher for enzymes than for lipids [14].  
 
The APS for lipids and lipoproteins generated from the new BV estimates presented 
here are not very different from those published in the online database. APS for 
imprecision is slightly stricter for HDLC (2.9% vs 3.7%) and Apo A1 (2.3% vs 3.3%). In 
general, the APS for bias are wider. Triglycerides are an exception (27.8% vs 26.0%), 
and Apo A1, where meta-analysis estimates provide more stringent APS (6.2% vs 9.1%). 
 
Generally, the meta-analysis-derived BV estimates could be used as a resource for 
laboratory professionals when to set APS. Nevertheless, there may be situations for 
the different lipids where a different model should be considered.  
 
In our study we have aimed to assess the effect of study design, differences in study 
population and sampling intervals on BV estimates. However, the large variations in BV 
estimates delivered by studies that appear similar makes it challenging to draw 
conclusions regarding the influence of these factors. This observation as exemplified in 
studies of triglycerides, where reported CVI estimates based on studies with weekly or 
monthly samplings in healthy individuals (26 studies) vary from 12% to 32%. This 
necessitates caution in interpretation and application of our data given the 




The 95% CI for the total cholesterol BV estimate derived from non-healthy subjects 
(dyslipidemia, diet, or pharmacological treatment, in a total of 9 subgroups) 
overlapped with the 95% CI observed for healthy subjects (55 subgroups). Our data 
therefore suggest that there are no differences between CVI in non-healthy and 
“healthy” subjects (Fig 1) studied with sampling intervals of more than one day. In 
practice this is an important assumption because in most clinical laboratories treated 
and non-treated diseased patients are routinely mixed with healthy subjects in 
everyday practice. This means that the same APS could be validly applied to the assay 
for general application. Interestingly CVI of TC seems to be lower in within-day studies, 
ranging from 2% to 5% (7 subgroups, Figure 1). This would indicate a requirement for a 
more stringent APS to be applied if several measurements are requested within a day.   
  
In short-term conditions it has been reported that there may be some differences in 
the magnitude of BV [6]. In stable disease, the homeostatic set point may be reset, but 
the variation around that set-point is thought to be like that of the non-diseased. Use 
of an RCV derived for healthy subjects may therefore be valid in stable disease. Short 
term illness leading to an acute phase reaction impacts on a range of proteins and it is 
known that TC falls significantly after myocardial infarction [6]. This makes it difficult to 
use RCV in this situation.  It is important to ensure that factors impacting BV are taken 
into account when evaluating a change in serial measurements in a particular 


















When reviewing the studies that met the inclusion criteria for the meta-analysis, visual 
inspection indicated that subgroup “a” from paper 290 had a CVI estimate that differed 
from other studies (Figure 1). Estimates in this study were based on 3 samples, at least 
a week apart, collected from 9 Chinese healthy men, with serum TC measured using an 
AU-5800 (Beckman Coulter). It was graded as C as testing of variance homogeneity was 
not described, but no other apparent factor apart from ethnicity could be identified to 
explain the unusual CVI estimate. Ethnicity did not appear to be an issue in a study that 
comparing BV data from Caucasian subjects (study 291) with an Hispanic population 
where no differences were observed.  More studies are needed across appropriate 
sampling periods to examine whether ethnicity may affect BV estimates. 
   
  
Triglycerides 
The point estimate from children (2 subgroups) and persons above the age of 75 years 
(4 subgroups) fell outside the CI of the meta-analysis estimate obtained in healthy 
adults below the age of 75, indicating that these age groups may have a different CVI. 
This observation agrees with that of other authors [23] and should be taken into 
consideration by laboratories supporting elderly or paediatric care services.  
 
On visual inspection it appears that within-day studies of TG may provide higher CVI 
estimates (7 subgroups, Figure 3). A possible explanation for this is that temporal 
changes in blood TG levels related to food intake. It is interesting to note that the Joint 
Consensus Statement from the European Atherosclerosis Society and European 
Federation of Clinical Chemistry and Laboratory Medicine recommends [24], in 
general, fasting is not a necessary pre-analytical requirement for lipid measurements 
except for TG.  
 
HDL-cholesterol 
On visual inspection it appears that CVI estimates for HDLC in the pediatric population 
(2 subgroups) are slightly higher than those for adults. No obvious differences were 
observed between estimates of non-healthy (n = 10 subgroups) and healthy subjects (n 
= 31 subgroups).  
 
Measured and calculated LDL-cholesterol, Apolipoprotein A1 and Apolipoprotein B 
There were no significant differences observed between BV estimates obtained from 
the Friedewald formula (n = 35 subgroups) and direct LDLC measurement (n = 10 
subgroups). The concordance of TG results obtained by the two methods has also been 
reported in one unique study (paper 255, BIVAC grade B). It was postulated in the 
report of that that in healthy subjects TG is usually less than 200 mg/dL, arrange where 
the Friedewald formula is valid and unaffected by TG [25]. There is only one paper 
where CVI of measured LDLC is clearly different from calculated LDLC (study 103). This 
was scored against BIVAC as a C study. It included patients with type 2 diabetes 
treated with statins. The studied population was divided into 2 groups treated either 

















of ten blood samples taken at intervals of 4 days. The results showed that in those 
patients taking simvastatin the CVI for calculated LDLC was 13.1% compared to 10.7% 
for measured LDLC. In those taking atorvastatin, the difference was much larger, with a 
CVI for calculated LDL being 10.3% and <1% for measured LDLC. To our knowledge, no 
other paper has demonstrated a similar finding which raises the possibility that this 
finding is artefactual.  
 
Conclusions 
This study provides updated estimates of CVI and CVG for measurands important in the 
context of CVD. They have been derived utilizing meta-analysis of data from BIVAC 
compliant studies. The meta-analysis-derived BV estimates, with CI, were generally of 
similar magnitude to those cited in the online 2014 BV database. Therefore, to adjust 
the laboratory performance to the new APS derived from these new robust estimates 
will require only minor changes for clinical laboratories.  Appraisal of the available 
studies of CVD relevant measurands with the BIVAC identified a small number of B 
papers and only one A paper. This observation indicates a requirement for delivery of 
new BIVAC compliant studies to make available BV data for the many important 
applications BV data such as identification and delivery of robust and valid APS and 
RCVs. Well characterized global BV estimates will in   future be made available on-line 
within a new EFLM hosted website. Laboratory professionals should however be aware 
of the potential confounders to the application of BV data. There is for example a 
possibility that there may be differences in CVI estimates between different 
populations, and in subgroup of populations, necessitating partitioning of data.  
Differences in BV associated with state of well-being and ethnicity identify a need for 
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Table 1. Demographics of BIVAC items in lipids papers 



























Table 1. Number of reviewed biological variation papers for lipids, the corresponding number of 
subgroups, and their Biological Variation Data Critical Appraisal Checklist (BIVAC) grade  
Measurand 
(serum or plasma) 
Nº papers A B C D Nº subgroups* 
Total Cholesterol 57 1 4 42 10 95 
Triglycerides 41 1 3 33 4 79 
HDL-Cholesterol 32 1 2 27 2 65 
LDL-Cholesterol (measured) 9 - 2 5 2 12 
LDL-Cholesterol (calculated) 19 1 2 16 - 37 
Apolipoprotein A1 12 - 1 11 - 21 
Apolipoprotein B 10 - 1 9 - 17 
*A paper may include two or more subgroups depending on the population or study design, for 
instance: different sex or age groups, sampling intervals, short or long term study duration, healthy or 

















Table 2. Numbers of CVI and CVG estimates for lipids included in and excluded from the meta-analysis 
and the CVI and CVG estimates derived from the meta-analysis calculation compared to the estimates 
reported in the online 2014 BV database. The last two columns show the desirable analytical 
performance specifications (APS) derived from the meta-analysis estimates. 
































CVI %  
(95% CI) 
CVG %  
(95% CI) 













5.9 15.3 2.9 9.3 
 





















































6.9 22.8 3.6 11.0 
 
*Number of estimates from different subgroups included in the same study combined to provide a 
common estimate included in the meta-analysis. 
CVAPS: 0.5 x CVI 






















Figure 1. Total Cholesterol CVI 
Figure 2. Total Cholesterol CVG 
Figure 3. Triglycerides CVI 
Figure 4. HDL - Cholesterol CVI 


























Figure 1. CVI and 95% confidence interval estimates for total cholesterol. The different 
symbols indicate that estimates are derived from studies identified as: 1) BIVAC A, B 
and C graded studies performed in healthy adults, 2) the same in elderly and pediatric 
subjects, 3) those in non-healthy subjects, 4) estimates derived from within-day 
studies, 5) studies with CVA higher than desirable APS based on the online 2014 BV 
database and 6) studies with less than 3 samples per subject. Publications (X axis) are 
identified by the articles number given in the supplemental Table 1, with letters 
































































































































































































































































Figure 2. CVG and 95% confidence interval estimates for total cholesterol. The different 
symbols indicate that estimates are derived from studies identified as: 1) BIVAC A, B 
and C graded studies performed in healthy adults, 2) the same in elderly and pediatric 
subjects, 3) those in non-healthy subjects and 4) estimates derived from within-day 
studies, 5) studies with CVA higher than desirable APS based on the online 2014 BV 
database and 6) studies with less than 3 samples per subject. Publications (X axis) are 
identified by the articles number given in the supplemental Table 1, with letters 


























































































































Figure 3. CVI and 95% confidence interval estimates for triglycerides. The different 
symbols indicate that estimates are derived from studies identified as: 1) BIVAC A, B 
and C graded studies performed in healthy adults, 2) the same in elderly and pediatric 
subjects, 3) those in non-healthy subjects and 4) estimates derived from within-day 
studies, 5) studies with CVA higher than desirable APS based on the online 2014 BV 
database and 6) studies with less than 3 samples per subject. Publications (X axis) are 
identified by the articles number given in the supplemental Table 1, with letters 




























































































































































































































Figure 4. CVI and 95% confidence interval estimates for HDL-cholesterol. The different 
symbols indicate that estimates are derived from studies identified as: 1) BIVAC A, B 
and C graded studies performed in healthy adults, 2) the same in elderly and pediatric 
subjects, 3) those in non-healthy subjects and 4) estimates derived from within-day 
studies, 5) studies with CVA higher than desirable APS based on the online 2014 BV 
database and 6) studies with less than 3 samples per subject. Publications (X axis) are 
identified by the articles number given in the supplemental Table 1, with letters 



















































































































































































Figure 5. CVI and 95% confidence interval estimates for LDL-cholesterol. The different 
symbols indicate that estimates are derived from studies identified as: 1) BIVAC A, B 
and C graded studies performed in healthy adults, 2) the same in elderly and 
pediatric subjects, 3) those in non-healthy subjects and 4) estimates derived from 
within-day studies, 5) studies with less than 3 samples per subject. Publications (X 
axis) are identified by the articles number given in the supplemental Table 1, with 









































































































































































































- Reliable biological variation (BV) estimates are necessary for optimal 
diagnosis and monitoring of cardiovascular risk. 
- The Biological Variation Data Critical Appraisal Checklist has been 
applied to systematically evaluate BV studies for lipids 
- This study provides updated and evidence-based estimates of within-
subject (CVI) and between-subject (CVG) values for lipids based on 
BIVAC-compliant studies, delivered by meta-analysis 
- Quality assessed BV data will in the future be made available in the 
EFLM Biological Variation Database.
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